Iso Plexis Corp ISO
We take great care to ensure that the data presented and summarized in this overview for IsoPlexis Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in ISO
Top Purchases
Top Sells
About ISO
IsoPlexis Corporation, a life sciences company, provides solutions for the development of curative medicines and personalized therapeutics in the United States, Canada, the United Kingdom, Belgium, France, the Czech Republic, Spain, Germany, Sweden, Italy, Israel, Switzerland, China and Taiwan, Singapore, Japan, Australia, and Korea. The company offers single cell proteomics platform, including instruments, chip consumables, and software that provides an end-to-end solution to view of protein function at an individual cellular level. It provides IsoLight and IsoSpark instruments; IsoCode chips that offer multiplexed chip solutions for single cell functional proteomics; CodePlex chips that provide multiplexed solutions for ultra-low volume bulk samples; and IsoSpeak software that offers dimensional data and automates analysis with an intuitive push button user interface to deliver same day single cell and bulk proteome visualizations, as well as research support and services, and post-warranty services. The company was incorporated in 2013 and is based in Branford, Connecticut.
Insider Transactions at ISO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 21
2023
|
Rajesh T. Khakhar VP Finance |
SELL
Sale (or disposition) back to the issuer
|
Direct |
14,583
-100.0%
|
-
|
|
Mar 21
2023
|
James R Heath Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
201,888
-100.0%
|
-
|
|
Mar 21
2023
|
Gregory P. Ho Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
6,064,661
-100.0%
|
-
|
|
Mar 21
2023
|
Richard W. Rew Ii SVP, GC and Secretary |
SELL
Sale (or disposition) back to the issuer
|
Direct |
20,000
-100.0%
|
-
|
|
Mar 21
2023
|
John G. Conley Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
100,752
-100.0%
|
-
|
|
Mar 21
2023
|
Sean Mackay Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
914,366
-100.0%
|
-
|
|
Mar 21
2023
|
Jing Zhou Chief Scientific Officer |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
1,200
-100.0%
|
-
|
|
Mar 21
2023
|
Nachum Shamir Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
50,253
-100.0%
|
-
|
|
Mar 21
2023
|
John Strahley Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
65,000
-100.0%
|
-
|
|
Mar 10
2023
|
James R Heath Director |
BUY
Exercise of conversion of derivative security
|
Direct |
201,888
+27.94%
|
$0
$0.4 P/Share
|
|
Jan 30
2023
|
John G. Conley Director |
BUY
Exercise of conversion of derivative security
|
Direct |
36,000
+16.55%
|
$0
$0.85 P/Share
|
|
Aug 31
2022
|
Nachum Shamir Director |
BUY
Open market or private purchase
|
Direct |
40,000
+44.32%
|
$40,000
$1.94 P/Share
|
|
Aug 30
2022
|
Nachum Shamir Director |
BUY
Open market or private purchase
|
Direct |
10,253
+50.0%
|
$10,253
$1.89 P/Share
|
|
Aug 25
2022
|
John Strahley Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+13.33%
|
$20,000
$2.0 P/Share
|
|
Aug 25
2022
|
Sean Mackay Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
15,000
+1.61%
|
$15,000
$1.99 P/Share
|
|
Aug 25
2022
|
Richard W. Rew Ii SVP, GC and Secretary |
BUY
Open market or private purchase
|
Direct |
20,000
+50.0%
|
$20,000
$1.99 P/Share
|
|
Aug 19
2022
|
Sean Mackay Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
100,166
+5.41%
|
$0
$0.28 P/Share
|
|
Aug 17
2022
|
John Strahley Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+21.43%
|
$15,000
$1.03 P/Share
|
|
Jun 03
2022
|
John Strahley Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+27.27%
|
$15,000
$1.03 P/Share
|
|
Apr 22
2022
|
John Strahley Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+33.33%
|
$12,500
$1.03 P/Share
|